




The Patent Office



INVESTOR IN PEOPLE




The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *Andrew Gersey*
Dated 24 December 1999

Patents Form 1/77

Patents Act 1977
(Rule 16)



The
**Patent
Office**

1/77

24APR98 E355613-18 000027
P01/7700 25.00 9808696.0
The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Request for grant of a patent
(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference	28.65286/001		
2. Patent application number (The Patent Office will fill in this part)	23 APR 1998		9808696.0
3. Full name, address and postcode of the or of each applicant (<i>underline all surnames</i>)	PROTEUS MOLECULAR DESIGN LIMITED Beechfield House Lyme Green Business Park Macclesfield Cheshire SK11 0JL		
Patents ADP number (<i>if you know it</i>)			
If the applicant is a corporate body, give country/state of incorporation	United Kingdom <div style="text-align: right; margin-top: 10px;">5653/42003 R.</div>		
4. Title of the invention	Peptide Derivatives		
5. Name of your agent (<i>if you have one</i>)	Frank B. Dehn & Co.		
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	179 Queen Victoria Street London EC4V 4EL		
Patents ADP number (<i>if you know it</i>)	166001		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (<i>if you know it</i>) the or each application number	Country	Priority application number (<i>if you know it</i>)	Date of filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day / month / year)
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (<i>Answer 'Yes' if:</i> a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))	Yes		

Patents Form 1/77



9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description	28
Claim(s)	0
Abstract	0
Drawing(s)	3

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date 23 April 1998

12. Name and daytime telephone number of person to contact in the United Kingdom

Anne R. Grant
0171 206 0600

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s) of the form. Any continuation sheet should be attached to this form.
- If you have answered 'Yes', Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

65286/001.599

PEPTIDE DERIVATIVES

The present invention relates to analogues or derivatives of the mammalian peptide hormones angiotensin I and angiotensin II, and to immuno-therapeutic uses of these in particular for the therapy and prophylaxis of conditions associated with the renin activated angiotensin system.

Angiotensin is a peptide involved in controlling arterial pressure in mammals. It is produced in two forms in the body as a result of a biochemical cascade known as the renin-angiotensin system (RAS), initiated by renin produced as a result of a fall in arterial pressure. In the RAS, represented schematically below, renin is released by the kidneys from stored pro-renin following a fall in arterial blood pressure, and acts enzymatically upon angiotensinogen to produce angiotensin I which is a decapeptide having the sequence Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu. Two amino acids from the C-terminus of angiotensin I are rapidly cleaved, by angiotensin converting enzyme (ACE), present in the endothelium of the lungs, generally within 1-2 seconds, to produce the octapeptide angiotensin II, having the sequence Asp-Arg-Val-Tyr-Ile-His-Pro-Phe.

Angiotensinogen -----> angiotensin I-----> angiotensin II
 renin angiotensin converting enzyme (ACE)

Angiotensin I is very short lived within the body and has mild vasoconstrictor activity. Alone therefore it has insignificant effect on the circulatory system. Angiotensin II, however, is a vasoactive peptide which has a profound effect on the circulatory system, as well as on the endocrine system. Elevated levels of RAS-activated angiotensin II cause vasoconstriction and renal retention of salt and water, both of which

contribute to increased arterial pressure (hypertension) which can lead to cardiovascular damage. Angiotensin II has been implicated in a number of other disease states, including congestive heart failure. Hypertension is a major risk factor for heart attacks and strokes and congestive heart failure is the disease with the highest mortality within a few years of onset. There is a need for effective therapies for combatting these and other diseases associated with the renin-angiotensin system.

Current treatment for these diseases includes intervention in the RAS system using small organic molecules. One approach attempts to inhibit ACE with inhibitors such as lisinopril, captopril and enalapril, agents which are now established in management of hypertension. These drugs have not however been entirely successful. It seems that inhibition of ACE is only partial. Furthermore, because ACE lacks substrate specificity, biotransformation of other metabolically active peptides, including bradykinin may also be inhibited, which is undesirable. In addition, these drugs need to be taken on a regular basis, often for long periods, such as for the majority of adult life. A major drawback, however, of these drugs is their undesirable side effects, including dry cough and a first dose hypotensive effect with dizziness and possible fainting. Since anti-hypertensive therapies invariably need to be taken long term, e.g. for up to 30 years and sometimes even longer, these adverse side effects can result in loss of patient compliance, particularly in the absence of short term clinical benefit in a mainly asymptomatic condition, severely limiting the usefulness of this therapeutic approach.

A more recent therapeutic approach involves drugs which are angiotensin receptor antagonists which are intended to block the activity of angiotensin II. Examples include Losartan and Valsartan. The agents which have been developed to date appear to be specific

for only the AT₁ angiotensin receptor; they therefore block the dominant vasoconstrictor effects of angiotensin II, and are better tolerated but do not affect other actions of the angiotensin hormones. There is accordingly a need for improved therapies of diseases associated with the RAS.

A potential approach in treating or preventing diseases or disorders associated with the activity of a hormone is to neutralise the effects of the hormone within the patient by immunotherapy i.e. by immunising the patient against the hormone such that the activity of the hormone is neutralised by specific anti-hormone antibodies. Such antibodies may be exogenously administered in passive immunisation or they may be generated *in situ* by active immunisation using an immunogen based on the hormone.

We have now developed new derivatives of angiotensin which are potent immunogens and which can be used in an immunotherapeutic approach to combat conditions associated with elevated levels of angiotensin II produced by the RAS.

In particular, derivatives of angiotensin have been developed in which one or more angiotensin peptides are coupled to a binder moiety, e.g. a peptide sequence, which facilitates attachment of the angiotensin peptide to an immunological carrier such as a protein or polypeptide to form an immunogenic conjugate capable in an immunised host of inducing antibodies which bind to angiotensin and neutralise its effects.

In one aspect, the present invention thus provides an angiotensin derivative comprising at least one angiotensin peptide moiety coupled to a peptide carrier-binding moiety.

The angiotensin peptide moiety may be any moiety, without necessarily having the biological activity of a native angiotensin (ie. native hormone activity at the receptor, including both angiotensins I and II), in the


body which is capable of acting as an immunomimic of native angiotensin peptides i.e. which immunologically mimics angiotensin so as to generate antibodies which bind to native angiotensin peptides. Thus, such a moiety may conveniently comprise an angiotensin peptide, preferably angiotensin I (a decapeptide of formula Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) or angiotensin II (an octapeptide of formula Asp-Arg-Val-Tyr-Ile-His-Pro-Phe), or a functionally equivalent variant thereof. Such variants may include modifications of the angiotensin I or II sequence by single or multiple amino acid substitution, addition or deletion and also sequences where the amino acid residues are chemically modified, but which nonetheless retain angiotensin immunogenic activity. Such functionally (ie. immunologically) equivalent variants may occur as natural biological variations, e.g. angiotensin of species other than human, or they may be prepared using known and standard techniques for example by chemical synthesis or modification, mutagenesis, e.g. site-directed or random mutagenesis etc. The important feature as regards the modification is that the angiotensin peptide retains the ability to act as immunomimic of native angiotensin. Thus for example, an amino acid may be replaced by another which preserves the physicochemical character of the angiotensin peptide or its epitope(s) e.g. in terms of charge density, hydrophilicity/hydrophobicity, size and configuration and hence preserve the immunological structure. "Addition" variants may include N- or C-terminal fusions as well as intrasequence insertion of single or multiple amino acids. Deletions may be intrasequence or may be truncation from the N- or C-termini. The term "angiotensin peptide" as used herein includes all native angiotensin peptides and their functionally equivalent variants.

The carrier-binding moiety serves as a means by

which the angiotensin peptide moiety may be attached to an immunological carrier, which will generally be a protein or polypeptide, and thus preferably contains an amino acid residue having a reactive side chain, via which the angiotensin derivative may readily be coupled to the carrier using standard coupling techniques. Advantageously such a side chain may contain a free hydroxyl, carboxyl or thiol group. Such an amino acid may thus conveniently be a cysteine, tyrosine, aspartic acid or glutamic acid residue or a derivative thereof such as N-acetyl cysteine.

The carrier-binding moiety may take the form of a peptide extension at the N- or C-terminal of an angiotensin peptide, or a peptide pendant from or disposed within a chain segment between two or more angiotensin moieties.

Viewed from a further aspect, the present invention can be seen to provide an angiotensin derivative of Formula I



wherein

A represents an angiotensin peptide moiety;

X represents an amino acid;

Y represents an amino acid having a side chain with a free -SH, -OH or -COOH group;

L represents an organic linker capable of binding a group $((A)-X_n)-$ at one or more sites, e.g. capable of binding up to 10 $(A)X_n$ moieties;

n and r are each = 0-20;

m and s are each ≥ 1 , e.g. 1 to 10, preferably 1, 2, 3 or 4; and

p, q and t are each 0 or 1;

with the proviso that if $m \geq 2$, then $p=1$, or if $s \geq 2$, then $q=1$.

Preferably A is an angiotensin peptide, and X may be attached at the N- or C-terminus of the angiotensin peptide.

Group L may be any organic linker structure, preferably however, it is a peptide chain, which may be linear or branched or a single amino acid residue, containing residues of natural or synthetic amino acids or pseudo-amino acids. However it may also represent a carboxyl- or amine-terminating dendritic or cascade polymer, for example a branched polyamine.

When $t=0$, it will be seen that the compounds of Formula (I) include derivatives wherein a carrier binding moiety (i.e. X-Y or X-L-Y) is attached at the N- or C-terminus of an angiotensin peptide, as a simple N- or C-terminal extension, or wherein multiple angiotensin peptide moieties are linked to a carrier-binding moiety terminating in a group Y, for example as a dendritic array or where the angiotensin moieties are attached at multiple sites on the carrier-binding moiety.

When $t=1$, it will be seen that the derivatives may take the form of a "dimer"-type structure wherein the carrier-binding group Y of the carrier-binding moiety is disposed with a chain segment of the derivative i.e. effectively between two or more angiotensin peptide moieties.

If $t=1$, and L is an amino acid residue or a peptide chain, L may be or include a "chain-inverting" amino acid or pseudo amino acid (i.e. a compound capable of linking two peptide moieties, e.g. a diamine or dicarboxylic acid), this being a compound capable of inverting or reversing the N- to C-terminal direction of the peptide chain. Such a compound will thus generally include two amino or two carboxylic acid groups, e.g. glutamic acid or a α,ω -alkylene diamine or α,ω -alkylene dicarboxylic acid. When $t=1$, it is furthermore preferred that the total number of groups ((A)-X_n) - does not exceed 8.

Preferred compounds of Formula (I) include those wherein n and r are each 0-10, preferably 1-6, and those wherein m and s are each ≤ 8 , preferably 1, 2 or 4.


Group X preferably represents an amino acid having no side chain or a hydrocarbyl side chain (preferably an alkyl, C_{3-7} cycloalkyl or cycloalkenyl, C_{3-7} cycloalkyl- or cycloalkenyl-alkyl, alkaryl, aralkyl or alkarylalkyl moiety in which each alkyl moiety may be saturated or unsaturated and contains up to 6 carbons and each aryl moiety is preferably a phenyl ring), particularly preferably an aliphatic side chain. Glycine, alanine, β -alanine, valine, leucine and isoleucine are preferred and glycine is especially preferred.

Group Y is preferably cysteine, tyrosine, glutamic acid or aspartic acid or a derivative thereof such as N-acetyl-cysteine.

Group L preferably contains at least one residue of an amino acid or pseudo amino acid containing at least two amine or carboxyl groups e.g. lysine, arginine, glutamic acid or aspartic acid, particularly where $t=0$. Conveniently, such a preferred group L is a linear or branched peptide chain, eg. containing 2 to 15 amino acid residues. Branching may, of course, occur by peptide bond formation at an amine or carboxyl group of an amino acid residue side chain, eg. at a side chain amine group of lysine or arginine or at a side chain carboxyl group of aspartic or glutamic acid. A group L comprising one or more, eg. 1 to 3, lysine residues is especially preferred. Branching may occur by peptide bond formation at both the α -amino and ϵ -amino groups of lysine.

Preferred compounds of Formula (I) thus include compounds of Formulae (II) to (IV):





wherein A, X, L, n and r are as hereinbefore defined and $m \geq 2$.

Where the compounds of Formula (IV) contain more than one (A) group, these are preferably attached at the same terminus i.e. preferably all are N-terminally or all are C-terminally attached.

In compounds of Formulae (II) and (III) where X is C-terminally attached to a group A being an angiotensin peptide, Y is preferably cysteine. Where X is attached to the N-terminus of A, Y is preferably N-acetyl-cysteine.



In Formulae (II) to (V), X_n or X_r are each preferably chains of 1 to 6 glycine residues.

In compounds of formula (IV), m is preferably 2 or 4.

In Formulae (III) to (IV), L is preferably lysine, -lys-(X)_u, -lys-lys-(X)_u, or -lys-lys-(X)_u-lys

wherein u is 0 to 10, preferably 0 to 6, and X is an amino acid as defined above.




Thus, preferred compounds of Formula (IV) are those of Formulae (VI) and (VII):




where A, X, Y, n and u are as hereinbefore defined, and K is lysine.

In the "dimer-type" derivatives of Formula (V) the angiotensin peptide moiety may preferably be a "reversed" or "inverted" sequence variant of an angiotensin peptide ie. an angiotensin peptide in which the order of the constituent amino acids is reversed.

Representative angiotensin derivatives according to the invention include:



(The A-(Gly)₁₋₂-moiety may be bonded to either the α-amino or the ε-amino group)



wherein A is angiotensin I or angiotensin II and A' is angiotensin I or antiotensin II or an inverted or reverse angiotensin I or angiotensin II sequence.

Although Glycine is preferred, aliphatic side chain amino acids may be used in place of one or more of the Gly residues in the above formula.

Although the peptide analogues of the invention when examined by computer-aided energy minimisation modelling are generally considered too small to be optimally immunogenic alone, it has been found that when coupled via the carrier-binding moiety to a carrier, these peptide analogues elicit a strong protective immune response. They are thus eminently suitable for use in immunotherapy against RAS-associated conditions. Without wishing to be bound by theory, it is believed that coupling of the peptides to a carrier by means of the carrier-binding moiety results in the analogues having substantially the same conformation as that of the native angiotensin peptides.

The new derivatives according to the invention may be generated using a number of standard techniques including, for peptides, the Merrifield solid phase method in which amino acids are added stepwise to a growing polypeptide linked to a solid matrix (reference needed) and conventional Fmoc chemistry. If desired, reactive side chain groups of the amino acids in the growing chain may be protected during the chain synthesis. Branched structures may be prepared by similar techniques.

Where the new derivatives are linear peptides these may also be prepared by recombinant DNA expression using techniques known in the art e.g. as described, for example, by Sambrook et al., in Molecular Cloning: A Laboratory Manual, Second Edition, 1989.

Thus the present invention also provides a nucleic acid molecule coding for the angiotensin peptide derivatives of the invention, and nucleic acid molecules with sequences complementary thereto.

According to a further aspect of the invention, we provide an expression vector comprising the said nucleic

acid molecule of the invention. Such a vector may be suitable for expression in microorganisms which may be prokaryotic or eukaryotic e.g. *E coli* or yeast, or in plant or animal e.g. mammalian cells.

According to a yet further aspect, the present invention provides a host organism transformed with a vector according to the invention.

The angiotensin derivatives of the invention, as is the case for other small molecules, may be of insufficient size to stimulate antibody formation alone and may thus need to be conjugated to a macromolecular carrier in order to stimulate antibody production and a protective immune response.

Thus according to a further aspect, the present invention provides an angiotensin derivative as defined above conjugated to a carrier, preferably a polypeptide carrier.

Coupling of the derivative of the invention to the carrier may be by methods known in the art for example by treatment with heterobifunctional linking agents. Where coupling is via a terminal cysteine (or N-acetyl cysteine), the linking agent may be m-Maleimidobenzoyl-N-hydroxysulphosuccinamide ester; in which case maleimide modifies one or more lysine side chains in the peptide carrier, and a thioether bond forms at the terminal cysteine residue. Other coupling reagents known in the art, eg carbodiimide coupling, may also be used.

Any carrier known in the art for such purposes may be used, including the purified protein derivative of tuberculin, tetanus toxoid, diphtheria toxoid, keyhole limpet haemocyanin or derivatives thereof.

Where the angiotensin derivative is a linear peptide and the carrier is a protein or polypeptide, the entire peptide conjugate may also be made by recombinant DNA methods wherein a nucleic acid molecule encoding the conjugated molecule is expressed in an appropriate host

cell.

The new angiotensin derivatives of the invention may be used in an immunotherapeutic approach to combatting diseases associated with elevated levels of angiotensin peptides, and represents an advantageous method compared to currently available methods. Patient compliance should be increased in that less frequent dosing than is the case with current therapies is involved, and undesirable side effects are avoided.

Thus according to a further aspect, the present invention provides a pharmaceutical composition comprising an angiotensin derivative according to the invention, or a conjugated angiotensin derivative according to the invention, together with one or more pharmaceutically acceptable carriers or excipients.

Viewed from a further aspect, the invention provides an angiotensin derivative according to the invention for use in therapy.

Viewed from a yet further aspect, the invention provides the use of an angiotensin derivative according to the invention in the manufacture of a medicament for use in combatting diseases associated with activation of the renin-angiotensin system. Such diseases include congestive heart failure and systemic hypertension.

Viewed from a still yet further aspect, the invention provides a method of combatting conditions associated with activation of the renin-angiotensin system comprising administering an angiotensin derivative according to the invention.

The angiotensin derivative according to the invention optionally conjugated to a carrier may be administered by all conventional methods including parenterally (e.g. intraperitoneally, subcutaneously, intramuscularly, intradermally or intravenously), topically (e.g. as a cream to the skin), intra-articularly, mucosally (e.g. orally, nasally, vaginally, rectally and via the intra-ocular route) or by

intrapulmonary delivery for example by means of devices designed to deliver the agents directly into the lungs and bronchial system such as inhaling devices and nebulisers, and formulated according to conventional methods of pharmacy optionally with one or more pharmaceutically acceptable carriers or excipients, such as for example those described in Remingtons Pharmaceutical Sciences, ed. Gennaro, Mack Publishing Company, Pennsylvania, USA (1990).

Such compositions are conveniently formulated in unit dosage form e.g. for mucosal, parenteral or oral administration.

Actual treatment regimes or prophylactic regimes, formulations and dosages will depend to a large extent upon the individual patient and may be devised by the medical practitioner based on the individual circumstances.

The type of formulation will be appropriate to the route of administration. For example, parenteral administration by subcutaneous or intramuscular injection may be with a sterile aqueous suspension of the conjugated analogue in PBS or water for injection, optionally together with one or more immunological adjuvants e.g. aluminium hydroxide, saponin, quil A, muramyl dipeptide, mineral or vegetable oils, vesicle-based adjuvants, non-ionic block co-polymers, or DEAE dextran. Additional components such as preservatives may be used.

The dosage for injection may be in the range 1-100 μ g peptide equivalent and the frequency of administration may be upwards of from once every three or six months, to once every year or once every five years.

For oral administration, the conjugated derivatives may be formulated as tablets, liquid, capsules etc. Dosages range from 1 to 1000 μ g peptide equivalent with dosing occurring at intervals dependent on

bioavailability of product.

According to a still yet further aspect, the present invention provides a method for achieving maximal blockade of angiotensin hormones comparable to or exceeding that achieved by existing therapies based on ACE inhibitors and/or angiotensin II receptor antagonists, said method comprising administering an angiotensin derivative according to the invention.

The invention will now be described in further detail in the following non-limiting Examples, with reference to the drawings in which:

Figure 1 is a graph showing antibody titres +/- sem, n=6 (dilution corresponding to 0.1 increase in OD) against time (sample day);

A = Control

B = Derivative 3 of Example 2

C = Derivative 1 of Example 2

D = Derivative 4 of Example 2

E = Derivative 2 of Example 2.

Figure 2 is a graph showing peak change in blood pressure following administration of A1 in control rats and in rats immunised with a conjugate of an analogue of A1 in groups C and J of Example 4.

Figure 3 shows recordings of mean blood pressure changes in response to A1 in animals of groups A and C of Example 4.

Example 1: Peptide generation.

Peptides were synthesised by the Fmoc strategy of solid phase peptide synthesis on a Protein Technologies, Symphony Peptide Synthesiser. The resin used was Tentagel S-NH₂ with a Rink Amide linker. The side chain protecting groups of the Fmoc amino acids used were Trt for Cys His, Asn and Gln, tBu for Tyr Thr, Asp, Glu and Ser; Boc for Lys and the indole N of Trp, Pmc for Arg.

Activation of the carboxyl groups was achieved using, TBTU/HOBt/DIPEA, all couplings were carried out in DMF. Deprotection of the Fmoc groups was achieved with 20% Piperidine in DMF. Cleavage of the peptides from the resin was carried out with 5%Anisole/5%Thioanisole/5%EDT/3%Water/2%TES in TFA for 1 hour. The peptides were purified by RP-HPLC using a 40mm x 210mm Deltapak C18 radial compression column on a Waters Deltaprep 4000 and characterised by MALDI-TOF on a Kratos Maldi 3 and by AAA.

For dendrimers Fmoc Lys(Fmoc)-OH is attached by the methods above and gives both α and ϵ amino groups free for peptide elongation. Quantities of Fmoc amino acids used have to be increased accordingly.

Rink Amide Linker = p-[(R,S--[1-(9H-Fluoren-9-yl)-methoxyformamido]-2,4-dimethoxybenzyl]-phenoxyacetic acid

Fmoc = 9-Fluorenylmethoxycarbonyl

Trt = Trityl, Triphenylmethyl

tBu = tertiary butyl

Boc = tertiary butyloxycarbonyl

Pmc = 2,2,5,7,8-Pentamethylchroman-6-sulphonyl

TBTU = 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate

HOBt = N-Hydroxybenzotriazole

DIPEA = Diisopropylethylamine

DMF = N,N Dimethylformamide

EDT = Ethanedithiol

TES = Triethylsilane

TFA = Trifluoroacetic acid

RP-HPLC = Reverse phase high performance liquid chromatography

MALDI-TOF = Matrix assisted laser desorption ionisation - time of flight

AAA = Amino acid analysis

Fmoc-Lys(Fmoc)-OH = α , ϵ di-9-fluorenylmethoxycarbonyl lysine

The following peptides were synthesized in this manner:

Angiotensin I-gly-cys	Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu Gly-Cys
Angiotensin II-gly-cys	Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-Gly-Cys
N-acetyl-Cys-Gly-Angiotensin I	N-acetyl-Cys-Gly-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu
N-acetyl-Cys-Gly-Angiotensin II	N-acetyl-Cys-Gly-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe

Example 2: Conjugation procedure.

To tetanus toxoid solution in phosphate buffered saline (PBS), a 60 molar excess of S-MBS, m-Maleimidobenzoyl-N-hydroxysulphosuccinimide ester is added and stirred for 2 hours at 4°C in a sealed vial.


Excess S-MBS crosslinker is removed by chromatography (gel exclusion, PD-10, G-25 sephadex column) in PBS. The activated tetanus toxoid peak is collected, assayed for free maleimido groups and used as below.

The resulting carrier protein solution is purged with N₂, and a 12 molar excess of angiotensin derivative peptide added. The resulting solution is stirred for 4 hours at 20°C in a sealed container.

The conjugate is purified from free peptide by gel exclusion chromatography as above. A final assay for loss of free maleimido groups is performed on a sample of the mixture to prove that all available sites are conjugated.

The final conjugate is diluted to a working concentration and formulated as desired.

The structure of S-MBS crosslinked conjugate with a linear C-terminal extended angiotensin peptide derivative (eg. derivatives (1) and (2) of Example 1) is shown below:



Following this procedure, angiotensin derivatives (1) to (4) of Example 1 were conjugated individually to aliquots of tetanus toxoid.

Example 3: Immunisation Studies.

The four angiotensin derivatives of Example 1, conjugated individually to aliquots of tetanus toxoid as described in Example 2, were formulated by absorption to 0.4% (w/v) aluminium hydroxide gel (Alhydrogel, Superfos s/a, Denmark) in a normal saline (0.9% (w/v)) vehicle.

All conjugates were used as 10 μ g/ml peptide equivalent solution.

Male Sprague-Dawley rats were used in 5 treatment groups, with 6 rats per group.

The treatment groups receive:

Vehicle, sterile saline	0.5 ml/rat
N-acetyl-cys-gly-Angiotensin I derivative immunotherapeutic	5 μ g peptide equivalent/rat in 0.5ml vehicle
Angiotensin I-gly-cys derivative immunotherapeutic	5 μ g peptide equivalent/rat in 0.5 ml vehicle

N-acetyl-cys-gly-Angiotensin II	5 µg peptide equivalent/
derivative immunotherapeutic	rat in 0.5 ml vehicle
Angiotensin II-gly-cys	5 µg peptide equivalent/
derivative immunotherapeutic	rat

The route used was subcutaneous and each rat receives 3 separate doses of the specified test article during the course of the study.

The bodyweight of each rat is recorded once a week throughout the experimental procedure.

Experimental procedure

In this initial investigation the core temperature of each rat is recorded, as part of the general physiological monitoring of the animals.

On day 1 and subsequently on days 22 and 43, the rats receive a single subcutaneous dose of the vehicle, or the test articles. Twenty four hours following each administration (days 2, 23 and 44) and on further days specified in table 1 a venous blood sample (0.5 ml) is subsequently taken while the rat is restrained.

Each sample of venous blood is collected in a glass tube, cooled on ice and allowed to clot, then centrifuged to yield serum within 45 minutes of sampling. Serum samples are frozen at approximately -20°C as soon as possible.

Table 1: Time Schedule of Study Procedures

Week	Day	Treatment	Blood Sample
1	1	Test articles, vehicle	
	2	No dosing	+
2	9	No dosing	+
	16	No dosing	+
3	22	Test articles, vehicle	
	23	No dosing	+
4	30	No dosing	+
5	37	No dosing	+
6	43	Test articles, vehicle	
	44	No dosing	+
7	51	No dosing	+
8	58	No dosing	+
9	65	No dosing	+
10	72	No dosing	+
11	79	No dosing	+
12	86	No dosing	+

Each serum sample was assayed for the generation by the treatment of an antibody response by titration of anti-angiotensin peptide-antibodies present in the sera by Enzyme Linked ImmunoSorbant Assay (ELISA).

This assay was performed as follows:

Coat the 96 well uniwell microtitre plates with 50 μ l detection substrate e.g. Angiotensin II-Gly-Cys-BSA (10 μ g peptide equivalent/well) for 1 hour at room temperature. At the same time place 50 μ l PBS into separate wells to act as a substrate blank.

Wash the plates 3 times with 200 μ l Phosphate Buffered Saline (PBS)/0.1% Tween 20.

Add 200 μ l/well of 3% (w/v) milk powder (Marvel) in PBS and leave for 1 hour at room temperature to block non-specific antibody binding.

Wash the plates 3 times with 200 μ l PBS/ 0.1% Tween 20.

Dilute the serum samples to a suitable dilution with PBS. Typical dilutions would be as follows:

- i) 1/100 - 5 μ l rats sera + 495 μ l PBS
- ii) 1/1000 - 20 μ l (i) + 180 μ l PBS .
- iii) 1/2000 - 10 μ l (i) + 190 μ l PBS
- iv) 1/5000 - 4 μ l (i) + 196 μ l PBS

Load the appropriate diluted sera (50 μ l) to appropriate wells and incubate at 20°C for 1 hour to permit substrate:antibody binding.

Wash the plates 3 times with 200 μ l PBS/0.1% Tween 20.

Dilute rabbit-antirat IgG peroxidase conjugate 1:5000 in PBS i.e. 1 μ l IgG peroxidase + 5 mls PBS. this binds to the rat serum antibody and allows antibody detection.

Add 50 μ l of the diluted IgG peroxidase to the appropriate wells and leave for 45 minutes at room temperature.

Wash the plates 3 times with 200 μ l PBS.

250 μ l aliquot of the peroxidase substrate 3,3',5,5' - tetra methyl benzidine (TMB) to 25 mls 0.1M sodium acetate buffer pH5.5 with 4 μ l 30% hydrogen peroxide.

Add 100 μ l of the prepared TMB substrate to the appropriate wells, including the blank wells. A colour producing reaction occurs where antibody/ substrate binding has occurred. Leave for 15 minutes at room temperature, then terminate the reaction with 50 μ l 10% sulphuric acid added to each well.

The plate is read for absorbance of light at 405 nm generated by the reaction of the peroxidase enzyme on the TMB substrate and is proportional to the amount of primary (anti-angiotensin) antibody bond. Results for the 4 sample conjugate formulations of derivatives (1) to (4) of Example 1 are shown in Figure 1.

The changes in antibody levels against angiotensin peptides can be seen over time, and are summarised below:

Immunogen	Peak titre	Day	Terminal titre (Day 86)
(B) N-acetyl-cys-gly-Angiotensin I	12,218 \pm 3576	86	As peak
(C) Angiotensin I-gly-cys	9,535 \pm 4423	30	5068 \pm 2038
(D) N-acetyl-cys-gly-Angiotensin II	15,726 \pm 8271	30	10,239 \pm 6544
(E) Angiotensin II-gly-cys	5090 \pm 2965	37	2011 \pm 1250

(A) is the control

This is the dilution of serum required for a 0.1 OD change from baseline levels in the ELISA assay.

In parallel with the antibody titre data, all animals were examined for gross physiological changes in body temperature, weight and general appearance, as an overall assessment of toxic or harmful effects.

No adverse effects were recorded on any of the 4 constrict treatment groups, showing that the treatments are effective in generating anti-angiotensin antibodies, without harmful physiological effects in the animals.

Example 4: Effects of active immunisation against angiotensin peptides on the pressor effects of exogenous angiotensin I (AI) in conscious rats

In this experiment to demonstrate the potential of active immunisation with angiotensin analogues, certain analogues of angiotensin I (AI) and angiotensin II (AII) were conjugated to carrier proteins which are good immunogens. These immunoconjugates were adjuvanted and shown in immunised rats to generate a strong anti-angiotensin immune response.

The immunised rats were examined with regard to inhibition of the pressor response to exogenous AI.

Materials and Methods

Angiotensin immunotherapeutic vaccine preparation

The angiotensin analogues used in this study were:

AI analogue is: N-acetyl-cysteine-glycine-angiotensin I

AII analogue is: N-acetyl-cysteine-glycine-angiotensin II

The analogues of AI and AII were prepared using a Symphony peptide synthesiser (Anachem).

The conjugation carrier proteins, tetanus toxoid (TT) (Chiron Behring, GmbH), keyhole limpet haemocyanin (KLH) (Biosyn, GmbH) and non toxic recombinant diphtheria toxin (DT) (Chiron Behring, GmbH), were activated for

conjugation using a suitable bivalent linker. The 'activated' carrier protein was separated from the excess cross-linker reagent by size exclusion chromatography.

The following conjugates were made

Sample Group	Conjugate
A	Saline control
B	AII analogue, TT carrier protein
C	AI analogue, TT carrier protein
D	AII analogue, DT carrier protein
E	AII analogue, KLH carrier protein
F	AII analogue, TT carrier protein
G	equal mix of AI and AII analogues TT carrier protein
H	AII analogue, TT carrier protein
J	AI analogue, TT carrier protein
K	AII analogue, TT carrier protein
L	AI analogue, TT carrier protein

Key: AI/AII Peptide analogues of angiotensin hormones
TT Tetanus toxoid
DT non-toxic recombinant Diphtheria toxin
KLH Keyhole Limpet Haemocyanin

An excess of the AI and/or AII analogues was mixed with the activated carrier proteins and allowed to react, after which AI/AII-carrier protein conjugates were separated from the remaining free analogue by size exclusion chromatography.

The conjugates were sterilised by filtration through a 0.2 μ m filter (Millipore) and formulated with adjuvant and saline vehicle to yield the appropriate vaccine for administration.

Alhydrogel® (Superfos S.A.) was the chosen aluminium hydroxide gel adjuvant for this study and 0.9% saline (Flowfusor®, Fresenius) the vaccine vehicle.

Table 2 shows the conjugate formulations administered to each of the treatment groups. The conjugates were formulated with aluminium hydroxide adjuvant, other than the conjugate of Group F which was formulated with DEAE adjuvant.

Immunisation and AI Challenge

Male, Sprague Dawley rats (initially 200-250 g: Harlan Olac: n=6 for all groups) were injected (0.5 ml, sc.) with saline or immunotherapeutic vaccines on the days specified in Table 2.

On day 61, under sodium methohexitone anaesthesia (40-60 mg kg⁻¹ i.p., supplemented as required), catheters were implanted in the distal abdominal aorta (via the ventral caudal artery) and right jugular vein. The following day, conscious rats were given increasing i.v. bolus (0.1 ml) doses of AI (3-60 pmol rat⁻¹), while mean systemic arterial blood pressure and heart rate were recorded. At the end of the experiment animals were given i.v. sodium pentobarbitone (100 mg) and a blood sample was taken by cardiac puncture for the measurement of anti-angiotensin antibodies by ELISA.

Table 2
Treatment regime, formulations, doses, injection frequency and experimental regimes for study

Group	Formulation	Days	Injections					Catheters	Challenge (AI)
			Vol/Dose						
			0	14	21	28	42		
A	Saline Control	0.2 ml	X		X		X	X	X
B	AII analogue, TT carrier protein, ALOH adjuvant	5 µg	X		X		X	X	X
C	AI analogue, TT carrier protein, ALOH adjuvant	5 µg	X		X		X	X	X
D	AII analogue, DT carrier protein, ALOH adjuvant	5 µg	X		X		X	X	X
E	AII analogue, KLH carrier protein, ALOH adjuvant	5 µg	X		X		X	X	X
F	AII analogue, TT carrier protein, DEAE adjuvant	5 µg	X		X		X	X	X
G	equal mix of AI and AII analogues TT carrier protein, ALOH adjuvant	2x2.5 µg	X		X		X	X	X
H	AII analogue, TT carrier protein, ALOH adjuvant	25 µg	X		X		X	X	X
J	AI analogue, TT carrier protein, ALOH adjuvant	25 µg	X		X		X	X	X
K	AII analogue, TT carrier protein, ALOH adjuvant	5 µg	X	X		X		X	X
L	AI analogue, TT carrier protein, ALOH adjuvant	5 µg	X	X		X		X	X

Key:

AI/AII Peptide analogues of angiotensin hormones
 TT Tetanus toxoid
 DT non-toxic recombinant Diphtheria toxin
 KLH Keyhole Limpet Haemocyanin
 DEAE Diethylaminoethyl cellulose
 ALOH Aluminium hydroxide gel

Angiotensin analogue antibody ELISA

ELISA plate wells (Anachem) were coated with 10 μ g peptide equivalents of either AI or AII conjugated to bovine serum albumin (BSA) as a carrier.

The coated wells were washed with PBS (0.2% w/v)/Tween (Sigma) and blocked with 3% Marvel before diluted sera from the vaccinated rats were incubated in their respective wells. The sera had been diluted in PBS (Sigma) over a range from 2,500-20,000 fold.

Immobilised antibodies were detected in the wells using a rabbit anti-rat IgG/horseradish peroxidase conjugate and revealed using 3,3'-5,5'-tetra-methyl benzidine with H₂O₂ (Sigma). The reaction was terminated after 15 min at 22°C by the addition of 10% (v/v) H₂SO₄ (Sigma).

Colour generated was determined by absorbance at 450nm using a Packard plate reader. The resultant absorbance readings were analysed by a statistical package (SAS Institute 1997) to determine titre.

Statistical analysis of blood pressure changes on AI Challenge

The maximum change in mean blood pressure and heart rate over their immediate pre-challenge values were calculated for each animal and each challenge dose. Differences between treated groups and unimmunised controls were assessed by ANOVA using Dunnett's test.

Dose response analysis

The main effect of immunisation was to cause a parallel shift in the blood pressure dose response of animals to AI challenge. To estimate the size of this shift, a

logistic model was derived and fitted to the dose response:

$$\Delta BP = \frac{\Delta BP_{\max}}{1+(d / ED_{50})^{-\alpha}} + \epsilon \quad \epsilon \sim N(0, \sigma^2)$$

where d is the dose of AI, BP_{\max} is the maximal change in blood pressure, α a shape parameter and ED_{50} is the dose of AI giving a half maximal response. Separate ED_{50} estimates were obtained for each animal. Significant differences between treatment groups and unimmunised controls were assessed by ANOVA of log-transformed ED_{50} values using Dunnett's multiple comparison test.

Results

Table 3 summarises some of the results, showing that active immunisation caused significant shifts in the pressor dose-response to AI and marked increases in antibody titres.

Clear effects on blood pressure are demonstrated with these treatments and the maximum dose shift (8.9x the control) are seen with a conjugate containing the AI analogue and tetanus toxoid on an aluminium hydroxide adjuvant.

Table 3 also demonstrates the relationship between anti-angiotensin antibody titre and response. In general, it can be seen that there is broad agreement between treatment induced titre and mean treatment induced dose shift, but no obvious dose response between groups C and J is apparent.

Figures 2 and 3 illustrate the results for control rats (Group A) and rats immunised with a conjugate of the AI

analogue and tetanus toxoid, presented on an ALOH gel adjuvant at a peptide equivalent dose of 5 μ g (low; Group C) and 25 μ g (high; Group J).

5 Conclusion

Treatment with a conjugate containing an AI analogue and tetanus toxoid on an aluminium hydroxide adjuvant gives a highly significant reduction in the pressor response to exogenous AI.

Table 3

Treatment	Median ED ₅₀	Mean treatment- induced dose shift	Anti-angiotensin antibody titre, ± s.e. mean (n=6)
15 A	8.9	-	0 0
B	39.6	4.5*	15300 ± 2100
C	79.1	8.9***	32100 ± 7800
D	19.6	2.2	9200 ± 2200
E	17.6	2.0	4700 ± 600
20 F	15.2	1.7	5500 ± 700
G	24.5	2.8	8300 ± 2000
H	38.2	4.3*	12100 ± 2500
J	74.7	8.4***	20100 ± 2300
K	13.9	1.6	5000 ± 900
25 L	43.0	4.8*	26100 ± 9400

Median AI bolus (pmol.rat⁻¹) to achieve half-maximal increase in mean blood pressure (ED₅₀) and corresponding anti-angiotensin antibody titres in control (group A) and immunised (groups B-L) rats. Significance probabilities adjusted for multiple comparisons by Dunnett's method (*=P<0.05, **=P<0.01, ***=P<0.001).

Time course of mean antibody titres +/- sem n=6





Fig. 1

Titre is dilution corresponding to 0.1 increase in OD

Figure 2

Pressor effects of AI in control rats (Group A) and rats immunised with AI analogue at a dose of 5 μ g (low, Group C) or 25 μ g (High, Group J)



Error bars show 95% confidence interval on mean, based on pooled within group standard deviation (n=6), shown for control group only.

Figure 3 : Recordings of mean blood pressure changes in response to AI (3, 18 and 60 pmol bolus dose) in representative animals from group A (control) and Group C (5 μ g dose)

